July/August

With drugs that achieve similar clinical outcomes, it will ultimately come down to financial differentiation that can determine which drugs lead the market.

The US Pharmacopeia (USP) Convention’s General Chapter draft guidelines have already raised the bar for hazardous drug management and imposed costs for compliance.

Biosimilars are a potential solution to the ever-growing problem of high specialty drug costs.

Specialty infusion pharmacy should be thought of in terms of superlatives, such as most complex and highest cost.

Health care spending in the United States is at the center of a loud, fractured debate mired in deep complexity.

With the right technology and information, we can better understand everything from clinical best practices to patient behaviors and even operational efficiencies.

A real-life look at pharmacist-led care management's ability to overcome barriers to care and adherence in HIV treatment.

Although there has been an increasing amount of legislation regarding it, as well, the Utah legislature has taken a very different approach.

As the number of specialty drugs has grown in the past decade, regional health systems and academic medical centers have stepped up to assert the power of integration and coordinated care by establishing and expanding their own specialty pharmacies.

Approximately 80% of manufacturers are already managing their products, many of which are oncology drugs, through a limited distribution model.

The meteoric rise in drug spending over the past 10 years has been driven by specialty therapeutics, while spending on traditional therapies has decreased.